行情

RGNX

RGNX

Regenxbio
NASDAQ

实时行情|Nasdaq Last Sale

48.19
-0.91
-1.85%
盘后: 48.19 0 0.00% 16:25 01/17 EST
开盘
49.35
昨收
49.10
最高
50.09
最低
48.18
成交量
41.52万
成交额
--
52周最高
63.21
52周最低
30.38
市值
17.77亿
市盈率(TTM)
-27.4603
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

RGNX 新闻

  • 特朗普法律团队首次官方回应弹劾 否认指控
  • 央视.46分钟前
  • 特朗普斥佩洛西偏帮拜登 弹劾审判律师团星光熠熠
  • 中国新闻网.50分钟前
  • LV总裁成新全球首富:和微软比我们的规模还是小
  • IT之家.1小时前
  • 世界首富易主!LV总裁取代亚马逊创始人成新首富
  • 海外网.1小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

RGNX 简况

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.
展开

Webull提供Regenxbio Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。